Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations

Vaccine

Volumn 28, Issue 1, 2009, Pages 171-178

  Nicholson, Karl G ^a   Thompson, Catherine I ^b   Klap, Jaco M ^c   Wood, John M ^d   Batham, Sally ^a   Newman, Robert W ^d   Mischler, Robert ^c   Zambon, Maria C ^b   Stephenson, Iain ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c CRUCELL HOLLAND BV   (Netherlands)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Immunogenicity; Pandemic vaccine; Serology

Indexed keywords

ALUMINUM POTASSIUM SULFATE; INFLUENZA VACCINE; LIVE VACCINE; VIROSOME VACCINE; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H9N2; MALE; PANDEMIC; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERODIAGNOSIS; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALUM COMPOUNDS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, VIROSOME; YOUNG ADULT;

EID: 70849110714     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.103     Document Type: Article

References (30)

1. Cong Y.L., Pu J., Liu Q.F., Wang S., Zhang G.Z., Zhang X.L., et al. Antigenic and genetic characterization of H9N2 swine influenza viruses in China. J Gen Virol 88 (2007) 2035-2041
2. Choi Y.K., Ozaki H., Webby R.J., Webster R.G., Peiris J.S., Poon L., et al. Continuing evolution of H9N2 influenza viruses in southeastern China. J Virol 78 (2004) 8609-8614
3. Mastrovich M.N., Krauss S., and Webster R.G. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology 281 (2001) 156-162
4. Saito T., Lim W., Suzuki T., Suzuki Y., Kida H., Nishimura S.I., et al. Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine 20 (2001) 125-133
5. Lin Y.P., Shaw M., Gregory V., Cameron K., Lim W., Klimov A., et al. Avian to human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 97 (2000) 9654-9658
6. Peiris J.S., Guan Y., Markwell D., Ghose P., Webster R.G., and Shortridge K.F. Cocirculation of avian H9N2 and contemporary 'human' H3N2 influenza A viruses in pigs in southeastern China: potential for genetic reassortment. J Virol 75 (2001) 9679-9686
7. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet 354 (1999) 916-917
8. Butt K.M., Smith G.J., Chen H., Zhang L.J., Leung Y.H., Xu K.M., et al. Human infection with an avian H9N2 influenza virus in Hong Kong in 2003. J Clin Microbiol 43 (2005) 5760-5767
9. http://www.promedmail.org/pls/otn/f?p=2400:1202:295812323296305::NO::F24 00_P1202_CHECK_DISPLAY,F2400_P1202_PUB_MAIL_ID:X,75394 (accessed 15 September 2009).
10. Wang M., and Fu C.X. Antibodies against H5 and H9 avian influenza among poultry workers in China. NEJM 360 (2009) 2583-2584
11. Stephenson I., Nicholson K.G., Glück R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 (2003) 1959-1966
12. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43 (2006) 1135-1142
13. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF-59 adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
14. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised trial. Lancet 370 (2007) 580-589
15. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Eng J Med 354 (2006) 1343-1351
16. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
17. Hehme N., Engelmann H., Künzel W., Neumeier E., and Sänger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191 (2002) 203-208
18. Ehrlich H.J., Müller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. New Eng J Med 358 (2008) 2573-2583
19. Kanra G., Marchiso P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23 (2004) 300-306
20. Boger W.P., and Liu O.C. Subcutaneous and intradermal vaccination with Asian influenza vaccine. JAMA 165 (1957) 1687-1689
21. Tauraso N.M., Gleckman R., Pedreira F.A., Sabbaj J., Yahwak R., and Madoff M.A. Effect of dosage and route of inoculation upon antigenicity of inactivated influenza virus vaccine (Hong Kong strain) in man. Bull World Health Org 41 (1969) 507-516
22. Nicholson K.G., Tyrrell D.A., Harrison P., Potter C.W., Jennings R., Clark A., et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7 (1979) 123-136
23. Ellis J.S., and Zambon M.C. Molecular investigation of an outbreak of influenza in the United Kingdom. Eur J Epidemiol 13 (1997) 369-372
24. Committee for Human Medicinal Products (CHMP). Note for guidance on harmonisation of requirements for influenza vaccines, CPMP/BWP/214/96. Circulaire no. 96-0661; 1997: 1-22.
25. Stephenson I., Das R.G., Wood J.M., and Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: international collaborative study. Vaccine 25 (2007) 4056-4063
26. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25 (2007) 6755-6763
27. US Food and Drug administration (FDA). Guidance for industry: clinical data needed to support the licensure of candidate pandemic influenza vaccines. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryIn formation/Guidances/Vaccines/ucm074786.htm (accessed 15 September 2009).
28. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., and Cryz Jr. S.J. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344 (1994) 160-163
29. Potter C.W. Determinants of immunity to influenza infection in man. Br Med Bull 35 (1979) 69-75
30. Stephenson I., Wood J.M., Nicholson K.G., and Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70 (2003) 391-398